Ryan Niederkohr, M.D. Slides are not to be reproduced without permission of author

Similar documents
F NaF PET/CT in the Evaluation of Skeletal Malignancy

PET/CT Frequently Asked Questions

Breast Cancer PET/CT Imaging Protocol

Value of true whole-body FDG- PET/CT scanning protocol in oncology and optimization of its use based on primary malignancy

Radiation Dosimetry for CT Protocols

HEALTHFIRST 2011 RADIOLOGY PROGRAM CODE LIST

Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010

05/02/ CPT Preauthorization Groupings Effective May 2, Computerized Tomography (CT) Abdomen 6. CPT Description SEGR CT01

Clinical indications for positron emission tomography

Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET

HIP RADIOLOGY PROGRAM CODE LISTS

New Visions in PET: Surgical Decision Making and PET/CT

Dr Sneha Shah Tata Memorial Hospital, Mumbai.

2012 CPT Radiology Codes Requiring Review Blue Cross and Blue Shield of Louisiana

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Zurich, January 19, 2018

Nuclear medicine in oncology. 1. Diagnosis 2. Therapy

PET/CT F-18 FDG. Objectives. Basics of PET/CT Imaging. Objectives. Basic PET imaging

Institution INSTRUCTIONS (I6) 1. This form is to be completed by a DESIGNATED STUDY NUCLEAR MEDICINE SPECIALIST

ROUTINE MRI PROTOCOLS: I. Abdomen Plus Post Gadolinium Screening Pelvis

objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University

Outcomes Report: Accountability Measures and Quality Improvements

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave

An Introduction to PET Imaging in Oncology

Austin Radiological Association Nuclear Medicine Procedure PET SODIUM FLUORIDE BONE SCAN (F-18 NaF)

CT Contrast Protocols for Different Organ Imaging

Low-Dose CT: Clinical Studies & the Radiologist Perspective

Radiology Pathology Conference

Bekir Tasdemir, 1 Zeki Dostbil, 1 Ali Inal, 2 Kemal Unal, 3 Sule Yildirim, 1 andf.selcuksimsek Introduction

AIM 2014 CPT Radiology & Cardiac Codes Requiring Review

Estimating Risks from CT Scans - in the Context of CT Scan Benefits

Using PET/CT in Prostate Cancer

SEER Summary Stage Still Here!

INDICATIONS AND USAGE

CT Radiation Risks and Dose Reduction

11/1/2014. Radiologic incidentalomas Ordering pitfalls Newer technology and applications

FieldStrength. Leuven research is finetuning. whole body staging

1 Introduction. 2 Materials and methods. LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1

RADPrimer Curriculum Breast Topics Covered Basic Intermediate 225

Learning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening

Cancer Program Report 2014

Emerging Referral Patterns for Whole-Body Diffusion Weighted Imaging (WB-DWI) in an Oncology Center

Austin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate)

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Introduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London

Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R

4D PET: promises and limitations

ADI Procedure Codes. August 2016 Revised April 2017 Page 1 of 7 ADI Procedure Codes

Lugano classification: Role of PET-CT in lymphoma follow-up

Recommendations for cross-sectional imaging in cancer management, Second edition

A 64 y.o. man presents to the hospital with persistent cough and hemoptysis. Fernando Mut Montevideo - Uruguay

POSITRON EMISSION TOMOGRAPHY (PET)

AMERICAN IMAGING MANAGEMENT

AMERICAN IMAGING MANAGEMENT

PET/CT for Therapy Assessment in Oncology

Austin Radiological Association TUMOR GLUCOSE METABOLISM STUDY (F-18-Fluorodeoxyglucose)

JHM-IRB Guidelines for Radiation Statements

Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report?

Thyroid Cancer: Imaging Techniques (Nuclear Medicine)

Imaging in Thyroid Cancer

Dose Estimates for Nuclear Medicine Procedures: What are they? Where do they come from?

CT PET SCANNING for GIT Malignancies A clinician s perspective

Nuclear Medicine in Thyroid Cancer. Phillip J. Koo, MD Division Chief of Diagnostic Imaging

Hybrid Imaging SPECT/CT PET/CT PET/MRI. SNMMI Southwest Chapter Aaron C. Jessop, MD

L hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active?

Clinical summary. Male 30 year-old with past history of non-seminomous germ cell tumour. Presents with retroperitoneal lymphadenopathy on CT.

Diagnostic Imaging Prior Review Code List 2 nd Quarter 2018

Radiation related cancer risk & benefit/risk assessment for screening procedures

When do you need PET/CT or MRI in early breast cancer?

Bone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors

THE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC)

Denominator Criteria (Eligible Cases): Patient encounter during the performance period (CPT): 78300, 78305, 78306, 78315, 78320

2010 Radiology Prior Authorization List for UnitedHealthcare s HealthChoice Members

Cancer Risks from CT Scans: Now We Have Data What Next?

Cancer Prevention & Control in Adolescent & Young Adult Survivors

FDG-PET/CT for cancer management

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

PET/CT in lung cancer

CT PROCEDURE REFERENCE GUIDE 2017

Oncologic Applications of PET Scanning

REVIEW. Distinguishing benign from malignant adrenal masses

Radiology. Undergraduate Radiology Sample Questions

Subject: PET Scan With or Without CT Attenuation. Original Effective Date: 11/7/2017. Policy Number: MCR: 610. Revision Date(s): Review Date:

Assessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose

APPENDIX G - Organ/Tissue Weighting Factors and Detriment/Risk Coefficients

Esophageal Cancer. What is the value of performing PET scan routinely for staging of esophageal cancers

Last Updated: 2/10/2017 Implementation date: 4/3/2017 Radiology & Cardiology Prior Authorization / Utilization Management Procedure List

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

Description MRI, TMJ C T Head Without Contrast C T Head With Contrast C T Head Without & With Contrast

Optimized PET/CT protocols: how much CT is needed? Increasing use of PET-CT. Imaging in Lymphoma

Radiation Oncology MOC Study Guide

PET/CT in breast cancer staging

Jeffrey C. Weinreb, MD, FACR Yale School of Medicine Yale-New Haven Hospital

Lung Cancer Screening: Radiologic and Clinical Implications. Katherine R. Birchard, M.D. University of North Carolina at Chapel Hill

Diagnostic Imaging Utilization Management and Consultation Management Programs Imaging Code Listing for Connecticut, Maine and New Hampshire

Staging recurrent ovarian cancer with 18 FDG PET/CT

Transcription:

Ryan Niederkohr, M.D.

CMS: PET/CT CPT CODES 78814 Limited Area (e.g., head/neck only; chest only) 78815 78816 Regional (skull base to mid-thighs) True Whole Body (skull vertex to feet)

SELECTING FIELD OF VIEW REGIONAL ( eyes to thighs ) Longer acquisition time 7-8 beds / 21-25 mins Fewer patients can be imaged per day Longer processing / reconstruction time Larger data set Greater radiation exposure Longer interpretation time LIMITED (e.g., chest) Shorter acquisition time 3-4 beds / 9-12 mins More patients could be imaged per day Shorter processing / reconstruction time Smaller data set Lesser radiation exposure Shorter interpretation time

QUESTION What is the estimated lifetime risk of a fatal cancer that is attributable to the ionizing radiation from a single CT scan of the abdomen in an adult (e.g., age 40 yrs)? A: 1 in 4 B: 1 in 2000 C: 1 in 5000 D: Negligible / too small to measure

ANSWER The correct answer is C. The risk of dying from cancer attributable to radiation exposure is dependent on dose and age at time of exposure. For a 40-year old man or woman, the risk of dying from cancer attributable to the ionizing radiation of one abdominal CT is approximately.02% = 1 in 5000. Answer A is incorrect. The lifetime risk of dying from cancer is 1 in 4. Answer B is incorrect. The lifetime risk of dying from cancer as a result of exposure to 1 rem of radiation is 1 in 2,000. Answer D is incorrect. Radiation risk is stochastic, meaning there is no threshold below which the risk is zero, or too small to measure. Reference: Brenner DJ, Hall EJ. Computed Tomography An Increasing Source of Radiation Exposure. N Engl J Med 2007;357;2277-2284.

1. Radiation Exposure kvp/mas Procedure W. body EDE Red marrow Breast Ovary Testes mrem PET 15mCi FDG 1700 720 510 950 720 140/100 CT skull to thighs 2500 240 110 440 510 140/100 CT chest 810 81 110 0 1 140/100 CT abd/pelvis 1400 110 4 440 260

2. Interpretation Time

2. Interpretation Time H/N 79 slices Thorax 100 slices Abdomen / Pelvis (remainder) 55 slices To midthighs 48 slices

3. Disease-specific considerations Primary cancers below the diaphragm: Consider inclusion of the chest (to evaluate for pulmonary metastases). Primary cancers above the diaphragm: Inclusion of the entire abdomen / pelvis may not be necessarily warranted. In some cases, inclusion of liver/adrenals may be useful. Other primary cancers (e.g., lymphoma, melanoma) Routine inclusion of chest, abdomen and pelvis may be warranted. Consider neck / extremities on a case-by-case basis

CT FIELD OF VIEW RECOMMENDATION HEAD/NECK Neck Chest + ± Abd / Pelvis ESOPHAGUS NSCLC LYMPHOMA ± + + + + + COLORECTAL + + www.nccn.org (2008)

Lung Cancer 1026 PET scans 592 with new lung cancer 35 with possible M1 disease outside of thorax 9 False Positive 26 True Positive Aquino SL, Fischman AJ. Chest 2004; 126: 755-60.

Seen on Limited Chest FOV Seen Only Outside Limited Chest FOV Liver 10 0 Adrenals 5 0 Spleen 2 0 Abdominal LN 3 0 Osseous Mets 12 1

Melanoma

Melanoma DISTRIBUTION OF PET ABNORMALITIES IN THE HEAD 296 SCANS 271 negative 25 positive 21 "anticipated" 4 "unanticipated" 2 True Positive 2 False Positive Niederkohr et al., Nuclear Medicine Communications 2007; 28: 688-95.

Melanoma DISTRIBUTION OF PET ABNORMALITIES IN THE LOWER EXTREMITIES 296 SCANS 237 negative 59 positive 35 "anticipated" 24 "unanticipated" 11 "Likely Benign" 5 "Equivocal" 8 "Likely Malignant" 0 True Positive 5 False Positive Niederkohr et al., Nuclear Medicine Communications 2007; 28: 688-95.

Head / Neck Cancer 38 patients primary tumor 26 PET/CT + Distant Malignancy / Metastasis 3 PET/CT + Lung Esophagus Sternum Wartski et al. Nucl Med Commun 2007;28:365-371

Head / Neck Cancer 175 scans in 133 patients Lesions below adrenal glands in 7 patients (5.3%) Malignant Liver/bone mets (2 pts, 1.5%) Pancreatic Cancer (1 pt, 0.75%) Renal cancer (1 pt, 0.75%) Benign Colon Uptake (2 pts, 1.5%) Inguinal LN s (1 pt, 0.75%) Andrei Iagaru et al., SNM 2007 and RSNA 2007

CONCLUSIONS More is not necessarily better in terms of FDG PET/CT field of view. Limited body region FDG PET/CT may become standard practice for certain malignancies. Maintain consistency with standard practice guidelines. Particularly when performed in conjunction with optimized CT Limit radiation exposure Limit false positive diagnoses

CONCLUSIONS Regional (torso) PET/CT may remain standard for other malignancies. For example: Lymphoma Primary malignancies in the abdomen/pelvis Known (or suspected) disease above and below the diaphragm.

CONCLUSIONS Whole body PET/CT may retain an important role in the evaluation of selected patients. For example: Primary tumor in the extremities Sarcoma, melanoma, etc. Known (or suspected) metastatic lesions in the extremities Based on symptoms, exam, or other imaging findings